• Overview
  • Eligibility
  • More info
  • Locations

A Non-interventional Study of Clinical Experience in Patients Prescribed Raxone® for the Treatment of Leber's Hereditary Optic Neuropathy (LHON) (NCT02771379)

This study is a multicentre, prospective, non-interventional post-authorisation safety study (PASS) of the clinical outcomes for patients with LHON treated with Raxone®. No medication will be provided as part of this study. Raxone® will be obtained through commercial channels.
  • Drug: Idebenone
    Raxone 900mg/day as per Raxone SmPC and medical judgement of treating physician.
    • Raxone®
Ages eligible for Study
all
Genders eligible for Study
All
Accepts Healthy Volunteers
No
Inclusion Criteria:
  • Patient prescribed Raxone® for the treatment of LHON;
  • Patient has completed an Informed Consent Form (ICF) indicating that he/she (or a legally acceptable representative) has been informed of all pertinent aspects of the study and has agreed to participate in the study;
  • Patient is not participating in any interventional study.
Exclusion Criteria:
  • No explicit exclusion criteria exist to avoid selection bias and to allow for documentation of routine clinical practice.

27 locations

Status:
recruiting
Type:
Observational
Phase:
-
Start:
31 August, 2016
Updated:
05 July, 2017
Participants:
250
Apply
A girl giving information about available additional trials.

FindMeCure helps you find, understand and join clinical trials from all over the world.

There are more clinical trials for your condition!